PROCEPT BioRobotics (NASDAQ:PRCT) Shares Down 4.8% – Here’s What Happened

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares dropped 4.8% during trading on Thursday . The stock traded as low as $21.17 and last traded at $20.9120. 125,719 shares changed hands during trading, a decline of 92% from the average daily volume of 1,546,816 shares. The stock had previously closed at $21.97.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on PRCT shares. Truist Financial set a $21.00 target price on PROCEPT BioRobotics in a research report on Wednesday, August 5th. TD Cowen cut their price target on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Piper Sandler decreased their price objective on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Finally, Evercore set a $23.00 target price on PROCEPT BioRobotics in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, PROCEPT BioRobotics has a consensus rating of “Hold” and an average target price of $25.09.

PROCEPT BioRobotics Stock Performance

The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The business has a 50-day moving average of $20.35 and a 200-day moving average of $23.69. The company has a market capitalization of $1.30 billion, a P/E ratio of -11.73 and a beta of 0.91.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. During the same quarter last year, the firm earned ($0.35) EPS. The company’s revenue was up 19.3% on a year-over-year basis. On average, sell-side analysts anticipate that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Insider Buying and Selling

In other news, CEO Larry Wood acquired 23,900 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 1,000 shares of company stock worth $28,480. Corporate insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. VELA Investment Management LLC raised its holdings in shares of PROCEPT BioRobotics by 62.0% in the second quarter. VELA Investment Management LLC now owns 113,722 shares of the company’s stock worth $2,568,000 after buying an additional 43,513 shares during the period. Corient Private Wealth LP boosted its holdings in PROCEPT BioRobotics by 89.9% during the 2nd quarter. Corient Private Wealth LP now owns 108,455 shares of the company’s stock valued at $2,449,000 after acquiring an additional 51,336 shares during the period. Amundi grew its position in PROCEPT BioRobotics by 329.8% in the 2nd quarter. Amundi now owns 100,539 shares of the company’s stock valued at $2,270,000 after acquiring an additional 77,145 shares during the last quarter. California State Teachers Retirement System grew its position in PROCEPT BioRobotics by 2,104.3% in the 2nd quarter. California State Teachers Retirement System now owns 1,547,069 shares of the company’s stock valued at $34,933,000 after acquiring an additional 1,476,885 shares during the last quarter. Finally, FirstWave Capital Management LLC grew its position in PROCEPT BioRobotics by 79.7% in the 2nd quarter. FirstWave Capital Management LLC now owns 144,408 shares of the company’s stock valued at $3,261,000 after acquiring an additional 64,069 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.